Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia
On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia
View 3 insightful presentations with Q&A from the New Therapies Session at the virtual ASCAT 2022.
Home
About
The MDT
Science & innovation
News & features
Events
Contact
The National Haemoglobinopathy Panel
Women’s and Children’s Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
